The Future of Aging and Longevity - Flipbook - Page 47
“A system built around
trea琀椀ng chronic disease
could gradually shi昀琀 toward
preven琀椀ng disease before
symptoms appear.”
healthy aging. Drugs originally developed to treat
obesity and type 2 diabetes—including me琀昀ormin,
SGLT2 inhibitors, and especially GLP-1 receptor
agonists—are a琀琀rac琀椀ng a琀琀en琀椀on for bene昀椀ts
that extend well beyond blood sugar control.
By improving metabolism, reducing chronic
in昀氀amma琀椀on, and suppor琀椀ng mitochondrial
func琀椀on, these therapies may also reduce the risk
of mul琀椀ple age-related diseases. Their rise re昀氀ects a
broader recogni琀椀on that obesity has become one of
the greatest obstacles to healthy aging in developed
countries. Addressing excess weight and metabolic
disease may currently o昀昀er the largest opportunity
to improve healthspan across popula琀椀ons.
Researchers are also turning their a琀琀en琀椀on
to one of aging’s most visible consequences:
the gradual loss of muscle mass and strength,
or sarcopenia. While regular exercise remains
the most e昀昀ec琀椀ve interven琀椀on, new therapies—
including myosta琀椀n inhibitors and experimental
molecules such as the mitochondrial pep琀椀de
MOTS-c—are being inves琀椀gated for their ability to
preserve muscle func琀椀on later in life.
More ambi琀椀ously, drugs known as rapalogs,
senoly琀椀cs that selec琀椀vely remove damaged cells,
and novel mitochondrial pep琀椀des are all being
tested for their abili琀椀es to target the biology
of aging rather than individual diseases. Each
approaches aging from a di昀昀erent angle, re昀氀ec琀椀ng
the growing understanding that there is unlikely to
be a single “an琀椀-aging” treatment. Instead, future
therapies will probably combine mul琀椀ple strategies
tailored to an individual’s biology.
Perhaps the most closely watched area of
research involves cellular reprogramming. Building
on discoveries recognized with the Nobel Prize,
scien琀椀sts have shown that a small set of genes—
known as the Yamanaka factors—can reset mature
cells to a more youthful state in the laboratory.
Researchers are now exploring whether carefully
controlled versions of this technology can
rejuvenate 琀椀ssues without increasing cancer risk.
Early human studies are beginning, supported in
part by ini琀椀a琀椀ves such as the $101 million XPRIZE
Healthspan compe琀椀琀椀on, raising the possibility
that damaged organs could one day be repaired
rather than replaced. S琀椀ll, many scien琀椀sts cau琀椀on
that the excitement surrounding age-reversal
technologies should not overshadow simpler
interven琀椀ons capable of producing broad public
health bene昀椀ts today.
AI is expected to play an increasingly
important role by analyzing con琀椀nuous streams of
data from wearable devices that monitor ac琀椀vity,
sleep, heart rate, glucose, and other physiological
signals. Rather than generalized health advice,
future AI systems may generate personalized
recommenda琀椀ons for nutri琀椀on, exercise, sleep,
and medica琀椀on based on an individual’s unique
biology and changing health status. Even so, many
researchers argue that the greatest gains may
come not from extending lifespan inde昀椀nitely,
but from transforming health care itself. A system
built around trea琀椀ng chronic disease a昀琀er it
develops could gradually shi昀琀 toward preven琀椀ng
disease before symptoms appear. Investments in
maintaining metabolic health, physical func琀椀on,
and resilience throughout adulthood could reduce
the enormous economic burden imposed by
diabetes, demen琀椀a, cardiovascular disease, and
other condi琀椀ons associated with aging.
For all the excitement surrounding longevity
science, most experts agree: The goal is not living
to 150. Instead, the vision is more a琀琀ainable—
and arguably more meaningful. By slowing the
biological processes that drive aging, tomorrow’s
medicine may allow many more people to
reach their nine琀椀es or even hundreds while
remaining physically ac琀椀ve, cogni琀椀vely sharp, and
independent. If that vision becomes reality, the
greatest achievement of aging research will not be
adding years to life but adding life to those years.
A D ECA D E O F P RO GRE S S , A D ECA D E TO ACT 43
